These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. Bex A; Powles T Expert Rev Anticancer Ther; 2012 Jun; 12(6):787-97. PubMed ID: 22716495 [TBL] [Abstract][Full Text] [Related]
24. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma]. Leroy X; Edeline J; Rioux-Leclercq N Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119 [TBL] [Abstract][Full Text] [Related]
25. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Karam JA; Wood CG Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966 [TBL] [Abstract][Full Text] [Related]
33. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. Kwan KG; Kapoor A Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804 [TBL] [Abstract][Full Text] [Related]
34. Improving outcomes in patients with advanced renal cell carcinoma. Sosman JA Expert Rev Anticancer Ther; 2008 Mar; 8(3):481-90. PubMed ID: 18366295 [TBL] [Abstract][Full Text] [Related]
35. Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma. Harshman LC; Srinivas S Expert Rev Anticancer Ther; 2007 Dec; 7(12):1749-61. PubMed ID: 18062749 [TBL] [Abstract][Full Text] [Related]
37. Update on novel agents in renal cell carcinoma. Tamaskar I; Pili R Expert Rev Anticancer Ther; 2009 Dec; 9(12):1817-27. PubMed ID: 19954293 [TBL] [Abstract][Full Text] [Related]
38. Is there a role for presurgical therapy for renal cell carcinoma? Calabrò F; Sternberg CN Expert Rev Anticancer Ther; 2010 Jun; 10(6):807-12. PubMed ID: 20553206 [TBL] [Abstract][Full Text] [Related]
39. Sequential use of targeted agents in the treatment of renal cell carcinoma. Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477 [TBL] [Abstract][Full Text] [Related]
40. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. Kirkali Z BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]